LYRA
NSCLyra Therapeutics Inc.
Manufacturing•Surgical and Medical Instrument Manufacturing
Watchlists:
Last updated: Wednesday 9th July 2025
9.25
+0.22 (2.44%)
Prev Close:9.03
Open:9.02
Bid:9.01
Ask:9.25
52 Week Range
3.8137.50
Volume:690,606
Mkt Cap:12 M
22
MarketXLS Rank ®
Weak Hold
Price Target
$10.64
+15.0%
Financials
Financial Statements
LYRA - Income Statement (Annual)
| Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Invalid date | |
|---|---|---|---|---|---|---|
| Accretion On Preferred Stock | 115000.0 | |||||
| Depreciation And Amortization | 471000.0 | 278000.0 | 1 M | 1000000.0 | 100000.0 | |
| General And Administrative Expense | 19 M | 19 M | 18 M | 14 M | 10 M | |
| Gross Profit Margin (profit Margin After CGS) | 2 M | 2 M | 1 M | 285000.0 | ||
| Impairment Of Capital Assets | 2 M | 2 M | ||||
| Misc Other Special Charges | 3 M | 4 M | ||||
| Net Income (loss) | -93 M | -63 M | -55 M | -44 M | -22 M | |
| Net Income Common Stockholders | -93 M | -63 M | -55 M | -44 M | -22 M | |
| Net Income Continuous Operations | -93 M | -63 M | -55 M | -43 M | -22 M | |
| Net Non Operating Interest Income Expense | 3 M | 4 M | 1 M | 102000.0 | 82000.0 | |
| Normalized Income | -78 M | -34 M | ||||
| Operating Income | -96 M | -67 M | -56 M | -44 M | -22 M | |
| Operating Income Before Depreciation (EBITDA) | -93 M | -62 M | -54 M | -43 M | -22 M | |
| Operating Expense | 98 M | 69 M | 56 M | 44 M | 22 M | |
| Other Gand A | 19 M | 19 M | 18 M | 14 M | 10 M | |
| Other Impairment Of Capital Assets | 2 M | 2 M | 1 M | |||
| Other Operating Expenses | 98 M | 69 M | 5 M | 6 M | 2 M | |
| Otherunder Preferred Stock Dividend | 115000.0 | |||||
| Preferred Stock Dividends | 115000.0 | |||||
| Research Expense | 44 M | 48 M | 39 M | 30 M | 13 M | |
| Restructring And Mn A Income | 11 M | |||||
| Salaries And Wages | 7 M | 6 M | ||||
| Total Income Available For Interest Expense (EBIT) | -93 M | -63 M | -55 M | -44 M | -22 M | |
| Total Revenues | 2 M | 2 M | 1 M | 285000.0 | ||
| Total Expenses | 98 M | 69 M | 56 M | 44 M | 22 M | |
| Total Revenue | 2 M | 2 M | 1 M | 285000.0 | ||
| Avgshs | 65 M | 996085.0 | 604713.0 | 259722.0 | 171804.0 | |
| Avgshsdt | 65 M | 996085.0 | 604713.0 | 171804.0 | ||
| Basiceps | -1.43 | -63.0 | -91.5 | -167.5 | -129.5 | |
| Basicepscont | -1.43 | -63.0 | -91.5 | -167.5 | -129.5 | |
| Depamor | 471000.0 | 278000.0 | 1 M | 1000000.0 | 100000.0 | |
| Dileps | -1.43 | -63.0 | -91.5 | -167.5 | -129.5 | |
| Dilepscont | -1.43 | -63.0 | -91.5 | |||
| Intinc | 3 M | 4 M | 1 M | 102000.0 | 82000.0 | |
| Netincdisc | -93 M | -63 M | -55 M | -44 M | -22 M | |
| Othincexp | 2 M | 2 M | -1 M | |||
| Pretaxinc | -93 M | -63 M | -55 M | -44 M | -22 M | |
| Resdev | 44 M | 48 M | 39 M | 30 M | 13 M | |
| Restruct | 11 M | |||||
| Sga | 19 M | 19 M | 18 M | 14 M | 10 M | |
| Shsout | 66 M | 1 M | 636595.0 | 260197.0 | 258951.0 | |
| Specincchg | -11 M | -2 M | ||||
| Taxprov | 39000.0 | 59000.0 | 13000.0 |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.